

[Link to Washington State Legislature Bill Information 2022](#)

Jan 10, 2022 – First day of session.  
 Feb 3, 2022 – Policy Committee Cutoff.  
 Feb 7, 2022 – Fiscal Committee Cutoff.  
 Feb 15, 2022 – House of Origin Cutoff.  
 Feb 24, 2022 – Policy Committee Cutoff – Opposite House.  
 Feb 28, 2022 – Fiscal Committee Cutoff – Opposite House.

March 4, 2022 – Opposite House Cutoff.  
 March 10, 2022 – Sine die. Last day allowed for regular session under state constitution.

TVW - <http://www.tvw.org/>

<b>Bills Requiring Active Involvement/Input</b>			
<b>Bill # /Companion</b>	<b>Short Title</b>	<b>Brief Description</b>	<b>Committee Action (subject to change)</b>
<a href="#">HB 1675/</a> <a href="#">SB 5507</a>	Dialysate and dialysis devices.	<p>HB 1675/SB 5507 amends RCW 18.64.257 and 69.41.032 (addressing the prescription of legend drugs by dialysis programs) to include additional entities related to dialysis programs and treatment. These entities are manufacturers of commercially available dialysate, manufacturers’ agents acting on behalf of the manufacturer, and dialysis devices used by home dialysis patients. The inclusion of these entities would allow dialysis product manufacturers to sell, deliver, possess, and/or dispense dialysis devices and associated legend drugs—particularly commercially available dialysate—directly to dialysis patients.</p> <p>Under the proposed act, dialysis product manufacturers and agents representing those manufacturers would be exempt from PQAC licensure if they are shipping commercially available dialysate used by home dialysis patients.</p>	<p><b><u>HB 1675</u></b>  <i>Pre-filed:</i> 12/20/2021  <i>Sponsors:</i> Representatives Bateman, Maycumber, Leavitt, Graham, Dolan, Cody, Griffey, and Riccelli  <i>Introduced:</i> 1/10/2022, referred to House Health Care &amp; Wellness Committee.  <i>Public hearing:</i> 1/12/2022  <i>Executive session:</i> 1/19/2022, substitute bill SHB 1675 introduced</p> <p><b><u>SHB 1675</u></b>  <i>Executive session:</i> <b>Moved through committee with “do pass” recommendation</b></p> <p><b><u>SB 5507</u></b>  <i>Pre-filed:</i> 12/7/2021  <i>Sponsors:</i> Senators Keiser, Muzzall, Lovick, and Wilson, C.</p>

<b>Bills Requiring Active Involvement/Input</b>			
<b>Bill # /Companion</b>	<b>Short Title</b>	<b>Brief Description</b>	<b>Committee Action (subject to change)</b>
			<i>Introduced: 1/10/2022, referred to Senate Health &amp; Long Term Care Committee Public hearing: 1/19/2022 @ 8:00 a.m. (subject to change)</i>
<a href="#"><u>SB 5546</u></a>	Insulin affordability.	<p>SB 5546 amends Washington state law pertaining to insulin affordability and the operations of the insulin work group (RCW 70.14.160). Section 1 of the bill amends language in RCW 48.43.780 to reduce the amount health plan enrollees must pay for a 30-day supply of prescription insulin drugs, from \$100 to \$35. This section also amends the date after which issued or renewed health plans must comply with the price change from January 1, 2021 to January 1, 2023.</p> <p>Section 3 of the bill addresses the insulin work group established in RCW 70.14.160 and HB 2662. The bill does not affect the number or type of representatives serving on the work group but expands the scope of the strategies considered in reducing insulin costs for individuals. Section 3.2(b) is an added subsection that requires the work group to design and review strategies for providing a once yearly 30-day supply of insulin to individuals on an emergency basis. This section also extends the deadline by which the work group must submit a preliminary report to the governor and legislature from December 1, 2020 to December 1, 2022.</p>	<p><b><u>SB 5546</u></b> <i>Pre-filed: 12/16/2021 Sponsors: Senators Keiser and Van De Wege Introduced: 1/10/2022, referred to Senate Health &amp; Long Term Care Committee. Public hearing: 1/19/2022</i></p>
<a href="#"><u>HB 1728</u></a>	Insulin affordability – Workgroup funding and report deadline.	<p>1728 HB would amend RCW 70.14.160 and create a new section pertaining to the insulin affordability workgroup. The deadline for the submission of the preliminary report “detailing strategies to reduce the cost of and total expenditures” of insulin for patients and the expiration of the section establishing the workgroup is extended from 2020 to 2022. The section expiration date is also extended from 2022 to 2024. A new section (Sec. 2.) is added that makes this act null and void if specific funding is not provided for this act by June 30, 2022.</p>	<p><b><u>HB 1728</u></b> <i>Pre-filed: 1/3/2022 Sponsors: Representatives Maycumber, Cody, Callan, Eslick, Macri, Ramos, Griffey, Riccelli, and Leavitt; by request of Health Care Authority</i></p>

Bills Requiring Active Involvement/Input			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
			<p><i>Introduced:</i> 1/10/2022, referred to House Committee on Health Care &amp; Wellness.  <i>Public hearing:</i> 1/10/2022  <i>Executive session:</i> 1/19/2022,  <b>moved through committee with a “do pass” recommendation</b></p>
<a href="#">SB 5547 / HB 1668</a>	<p>Expanding regulatory authority over cannabinoids.</p>	<p>SB 5547 would authorize the Liquor and Cannabis Board (board) to regulate all cannabinoids that may be impairing, regardless of origin, and would direct the board to adopt rules related to cannabinoid products and Cannabis isolates, except those authorized as a drug by the federal Food and Drug Administration (FDA).</p> <p>This would move jurisdiction over some identified substances from the Pharmacy Quality Assurance Commission (PQAC) to the Liquor and Cannabis Board (LCB). These substances include forms of tetrahydrocannabinol (THC) other than delta-9 THC, which has previously been placed in LCB’s jurisdiction.</p>	<p><b><u>SB 5547</u></b>  <i>Pre-filed:</i> 12/16/2021  <i>Sponsors:</i> Senators Keiser and Schoesler  <i>Introduced:</i> 1/10/2022, referred to Senate Labor, Commerce &amp; Tribal Affairs Committee.  <i>Public hearing:</i> 1/20/2022 @ 8:00 a.m.</p> <p><b><u>HB 1668</u></b>  <i>Pre-filed:</i> 12/20/2021  <i>Sponsors:</i> Representatives Kloba, Wylie, and Young  <i>Introduced:</i> 1/10/2022, referred to Senate Labor, Commerce &amp; Tribal Affairs Committee.  <i>Public hearing:</i> 1/13/2022  <i>Executive session:</i> 1/21/2022 @ 10:00 a.m.</p>

<b>Bills Requiring Active Involvement/Input</b>			
<b>Bill # /Companion</b>	<b>Short Title</b>	<b>Brief Description</b>	<b>Committee Action (subject to change)</b>
<a href="#">SB 5767</a>	Regulating hemp-derived cannabinoids.	<p>The bill requires LCB to adjust their regulations regarding cannabinoids and cannabis product testing, and lab standards. This includes LCB regulation regarding flower lots, batch testing; and laboratory testing standards that require certain tests to be completed on each flower lot, such as moisture analysis, foreign matter screening, microbial, mycotoxins and others. This bill adds several definitions and defines different types of cannabinoids.</p> <p>The bill may require the department to amend 246-70 WAC, depending on what LCB would need to change in their rules. We may need to amend our chapter regarding heavy metal screening and mycotoxin screening depending on how it affects LCB's rulemaking.</p>	<p><b><u>SB 5767</u></b>  <i>Sponsors:</i> Senators Stanford, Rivers, and Hasegawa  <i>Introduced:</i> 1/11/2022, referred to Senate Labor, Commerce &amp; Tribal Affairs Committee.  <i>Public hearing:</i> 1/20/2022 @ 8:00 a.m.</p>
<a href="#">HB 1852 / SB 5840</a>	Language requirements for prescription drug labels.	<p>Starting on January 1, 2023, a licensed pharmacy or nonresident pharmacy must provide translated directions upon request for use and side effects of prescription drugs. The Pharmacy Quality Assurance Commission (commission) is charged with determining the languages for which translation is required, and fifteen (15) languages must be chosen. The commission will build the list of languages based on the percent of the population of Washington that speaks the language, and this list must be reassessed and updated every five (5) years. The commission is also responsible for making the translations of directions for use and common side effects and developing signage to notify the public of the availability of translation services.</p> <p>Licensed pharmacies and nonresident pharmacies are not required to provide their own translated directions to patients, either within or beyond the list of fifteen languages determined by the committee. Pharmacies may provide their own translated directions for use and side effects but are only responsible for the accuracy of the English language directions.</p>	<p><b><u>HB 1852</u></b>  <i>Pre-filed:</i> 1/7/2022  <i>Sponsors:</i> Representatives Thai, Cody, Gregerson, Macri, Santos, Slatter, Valdez, Pollet, and Riccelli  <i>Introduced:</i> 1/10/2022, referred to House Committee on Health Care &amp; Wellness.  <i>Public hearing:</i> 1/17/2022</p> <p><b><u>SB 5840</u></b>  <i>Sponsor:</i> Senator Keiser  <i>Introduced:</i> 1/12/2022, referred to Senate Health &amp; Long Term Care Committee.</p>
<a href="#">SB 5753</a>	Enhancing the capacity of health profession boards,	It modifies membership and quorum requirements for the following regulatory bodies: Dental Quality Assurance Commission, the Veterinary Board of Governors, the Board of Physical Therapy, the Board of Massage, and the Board of Nursing Home Administrators. It authorizes the Pharmacy	<p><b><u>SB 5753</u></b>  <i>Pre-filed:</i> 1/7/2022  <i>Sponsor:</i> Senator Robinson</p>

Bills Requiring Active Involvement/Input			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
	commissions, and advisory committees.	Commission to use the same regulatory delegation for facilities enforcement that it currently does for pharmacy professionals. It harmonizes all boards and commissions as Class 5 Groups under Chapter 43.03 RCW. And finally, the bill removes US citizenship as a prerequisite to serve on boards, commissions, or committees.	<i>Introduced: 1/10/2022, referred to Senate Health &amp; Long Term Care Committee. Public hearing: 1/21/2022 @ 8:00 a.m. (testimony requested)</i>
<a href="#">SB 5660</a>	Establishment of a psilocybin board.	<p>This bill creates a system similar to Oregon Measure 109 in which, following an 18-month program development period, individuals aged 21 or older may consume psilocybin products for purposes of wellness, provided that the consumption takes place within licensed service centers, under the supervision of licensed facilitators, and using products created and tested by manufacturers and testers licensed by the Washington State Department of Health (DOH). It directs DOH to (including, but not limited to):</p> <ul style="list-style-type: none"> <li>• Establish a Washington Psilocybin Advisory Board with 20-23 members appointed by the Governor or designated by statute to provide advice and recommendations to DOH related to this new statute.</li> <li>• Publish information relating to the safety and efficacy of psilocybin</li> <li>• Develop a program by January 1, 2024 to regulate psilocybin products</li> <li>• Adopt requirements and guidelines for psilocybin services</li> <li>• Establish a code of conduct, education standards, and guidelines for psilocybin facilitators</li> <li>• Establish quality and safety standards for psilocybin products</li> <li>• Establishes regulations and location guidelines for licensure of psilocybin businesses</li> </ul> <p>The bill also:</p> <ul style="list-style-type: none"> <li>• Establishes a misdemeanor offense for falsification of identification and establishes civil penalties for violations of psilocybin rules.</li> <li>• Preempts local jurisdictions from establishing local licenses or taxes related to the manufacturing or sale of psilocybin.</li> </ul>	<p><b><u>SB 5660</u></b>  <i>Pre-filed: 1/5/2022</i>  Sponsors: Senators Salomon, Lovelett, Kuderer, Pedersen, Saldaña, Trudeau, and Wellman  <i>Introduced: 1/10/2022, referred to Senate Health &amp; Long Term Care Committee.</i></p>

Bills Requiring Active Involvement/Input			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
		<ul style="list-style-type: none"> <li>Prohibits an employer from discriminating against, requiring testing for, or discharging an employee for receiving psilocybin services</li> </ul>	
<a href="#">HB 1863</a>	Authorizing the prescriptive authority of psychologists.	<p>The bill adds psychologists to the list of professions able to prescribe medication, if a currently licensed psychologist meets the following criteria:</p> <ul style="list-style-type: none"> <li>Successfully complete a qualifying master’s degree, which includes psychopharmacology studies and supervised experience treating patients and prescribing medication (Sec 3 (2)(c));</li> <li>Successfully complete an 80-hour supervised clinical experience in physical assessment (Sec 3 (2)(d));</li> <li>Successfully complete a postdoctoral prescribing psychology fellowship of a minimum 500 hours and 100 individual patients (Sec 3 (2)(e)); and</li> <li>Pass a relevant examination (Sec 3 (2)(f)).</li> </ul> <p>The bill also:</p> <ul style="list-style-type: none"> <li>Excludes opioids from medication that may be prescribed (Sec 4(4))</li> <li>Requires the Examining Board of Psychology to work with the medical commission when creating administrative rules establishing standards for certifying prescribing psychologists (Sec 6(4)(c)).</li> <li>Sec 5 also adds a 10<sup>th</sup> board member and a requirement one of the board members must be an expert in psychotropic prescribing. <ul style="list-style-type: none"> <li>Currently, there are seven professional and two public board members; SB 5753 proposes adding two additional public members</li> </ul> </li> </ul>	<p><b><u>HB 1863</u></b>  <i>Pre-filed:</i> 1/7/2022  <i>Sponsors:</i> Representatives Macri, Goodman, and Simmons  <i>Introduced:</i> 1/10/2022, referred to the House Health Care &amp; Wellness Committee.</p>
<a href="#">SB 5743</a>	Designating kratom as a controlled substance.	<p>SB 5743 amends RCW 69.50.204 to classify mitragynine and 7-hydroxymitragynine, substances commonly known as kratom, as Schedule I drugs. A new section is added to justify the decision via emergency declaration: “This act is necessary for the immediate preservation of the public peace, health, or safety, or support of the state government and its existing public institutions, and takes effect immediately.”</p>	<p><b><u>SB 5743</u></b>  <i>Pre-filed:</i> 1/7/2022  <i>Sponsor:</i> Senator Honeyford  <i>Introduced:</i> 1/10/2022, referred to Senate Law &amp; Justice Committee.</p>

<b>Additional Bills to Watch (Not in PQAC Jurisdiction)</b>		
<b>Bill # /Companion</b>	<b>Short Title</b>	<b>Committee Action (subject to change)</b>
<a href="#">SB 5532</a> / <a href="#">HB 1671</a>	Prescription drug affordability board.	<p><b><u>SB 5532</u></b>  <i>Pre-filed:</i> 12/10/2021  <i>Sponsors:</i> Senators Keiser, Robinson, Conway, Hasegawa, Pedersen, Randall, Stanford, Wilson, C.  <i>Introduced:</i> 1/10/2022, referred to Senate Health &amp; Long Term Care Committee.  <i>Public hearing:</i> 1/19/2022</p> <p><b><u>HB 1671</u></b>  <i>Pre-filed:</i> 12/20/2021  <i>Sponsor:</i> Representatives Riccelli, Leavitt, Bateman, Valdez, Cody, Macri, Paul, Simmons, Chopp, Tharinger, Kloba, Pollet, Ormsby, Harris-Talley, and Taylor.  <i>Introduced:</i> 1/10/2022, referred to House Health Care &amp; Wellness Committee.</p> <p><i>Division track – Monitoring for amendments</i></p>
<a href="#">HB 1813</a> / <a href="#">SB 5811</a>	Pharmacy choice – Pharmacy benefit manager rules.	<p><b><u>HB 1813</u></b>  <i>Pre-filed:</i> 1/6/2022  <i>Sponsors:</i> Representatives Schmick, Macri, Graham, and Chambers  <i>Introduced:</i> 1/10/2022, referred to House Health Care &amp; Wellness Committee.</p> <p><b><u>SB 5811</u></b>  <i>Sponsors:</i> Senator Rivers, Keiser, and Short  <i>Introduced:</i> 1/11/2022, referred to Senate Health &amp; Long Term Care Committee.</p> <p><i>Division track – Monitoring for amendments</i></p>
<a href="#">HB 1821</a>	Definition of established relationship for purposes of audio-only telemedicine.	<p><b><u>HB 1821</u></b>  <i>Pre-filed:</i> 1/6/2022  <i>Sponsors:</i> Representatives Schmick, Riccelli, Cody, and Graham  <i>Introduced:</i> 1/10/2022 and referred to House Committee on Health Care &amp; Wellness.  <i>Public hearing:</i> 1/17/2022 @ 1:30 p.m.</p>

<b>Additional Bills to Watch (Not in PQAC Jurisdiction)</b>		
<b>Bill # /Companion</b>	<b>Short Title</b>	<b>Committee Action (subject to change)</b>
<a href="#">SB 5765</a>	Relating to the practice of midwifery.	<b><u>HB 5765</u></b> <i>Sponsors:</i> Senators Randall, Keiser, Conway, Das, Hasegawa, Lovelett, Mullet, Robinson, Saldaña, Stanford, Trudeau, Wilson, C. <i>Introduced:</i> 1/11/2022, referred to Senate Health & Long Term Care Committee.
<a href="#">HB 1874</a>	Reducing licensing barriers for those with previous arrest.	<b><u>HB 1874</u></b> <i>Sponsors:</i> Representatives Vick, Dufault, Hoff, Jacobsen, Leavitt, Simmons, Corry, Senn, Peterson, Goodman, Riccelli, Davis, Macri, and Young <i>Introduced:</i> 1/11/2022, referred to House Consumer Protection & Business Committee. <i>Public hearing:</i> 1/17/2022 <i>Executive session:</i> 1/20/2022 @ 10:00 a.m.
<a href="#">SB 5542</a>	Related to the practice of optometry.	<b><u>SB 5542</u></b> <i>Pre-filed:</i> 12/14/2021 <i>Sponsors:</i> Senators Cleveland, Rivers, Conway, Lovick, and Robinson <i>Introduced:</i> 1/10/2022, referred to Senate Health & Long Term Care Committee.
<a href="#">SB 5794</a>	Behavior health condition prescription drug coverage.	<b><u>SB 5794</u></b> <i>Sponsors:</i> Senators Dhingra, Kuderer, Frockt, Hasegawa, Lovelett, Randall, Van De Wege, and Wilson, C. <i>Introduced:</i> 1/11/2022, referred to Senate Health & Long Term Care Committee.  <i>Division track – Monitoring for amendments</i>